Stay updated with breaking news from Randomized Controlled Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from Study 2 of the Phase 3 SELECT-AXIS 2 clinical trial in adults with active...
AbbVie to Present Analysis Evaluating Continuous RINVOQ® (upadacitinib) Treatment in Psoriatic Arthritis for More Than One Year at EULAR 2021 Virtual Congress - In SELECT-PsA 2, 29 percent of bDMARD-IR patients treated with continuous RINVOQ (upadacitinib, 15 mg, once daily) achieved minimal disease activity at 56 weeks, which was consistent with improvements from baseline seen at week 24[1],[2] - The safety results of RINVOQ 15 mg were consistent with previously reported results in rheumatoid arthritis, with no new significant safety risks identified[1],[3] - Full results to be presented at...
ABBVie today announced results of an analysis from the Phase 3 SELECT-PsA 2 clinical trial, showing that continuous treatment with RINVOQ ® resulted in sustained improvements in disease activity for more than one year among patients with active psoriatic arthritis who have responded inadequately to one or more biologic disease modifying anti-rheumatic drugs . 1 At week 56, 29 percent of patients treated with ...
Transgene Expands Phase II Clinical Trial of Therapeutic Vaccine TG4001 in Combination With Avelumab Versus Avelumab Monotherapy in Patients With HPV16-positive Anogenital Cancers - Trial will focus on patients without liver metastases, based on encouraging data in Phase Ib/II study - Trial targets indications where clinical outcomes can be improved versus standard therapeutic options and immune checkpoint inhibitors ("ICIs") - Continued clinical collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to conduct the expanded Phase II study Regulatory News: Transgene (Paris:TNG) (Euro...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy ... Helsinn Healthcare S.A.February 18, 2021 GMT Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safety Lugano, Switzerland, February 18, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to note two recent journal publications on the use of mechlorethamine gel 0.016% as a topical...